Lyon: INNOVENT BIO (01801) achieved product revenue in the first half of the year that far exceeded expectations, serving as a positive catalyst for the stock price.

14:45 05/08/2026

Given the market's earlier concerns that anti-corruption measures might hinder the pharmaceutical industry's performance in the first half of the year, the recent sales performance of products is particularly encouraging.

Lyon released a research report stating that INNOVENT BIO (01801) announced product revenue of 8.2 billion RMB for the first half of 2026, a year-on-year increase of 55%, far exceeding market expectations of 6.9 billion RMB. Considering the market's previous concerns that anti-corruption measures might weigh on the pharmaceutical industry's performance in the first half of the year, this remarkable product sales performance is particularly encouraging and is believed to serve as a positive catalyst for the stock price today.

HK Stock Market Move | APEX ACE HLDG (06036) surged over 18% during trading, expecting the net profit attributable to shareholders for the first half of the year to grow to HKD 130 million to HKD 140 million compared to the same period last year.

HK Stock Market Move | The decline in storage concepts is significant, and the revenue guidance from US storage giants falls short of expectations, resulting in a transmission of sluggish sentiment to the Asia-Pacific market.

HK Stock Market Move | U-PRESID CHINA (00220) rose over 3% after results, with a mid-term profit attributable to shareholders of 1.402 billion yuan, an increase of 8.99% year-on-year.